Genocea Biosciences, Inc. / Fundamentals
Income statement
- Net revenue
€232.62K - Cost of goods sold
€0.00 - Gross profit
€232.62K - SG&A expenses
€12.61M - R&D expenses
€36.80M - EBITDA
-€32.04M - D&A
-€581.55K - EBIT
-€47.75M - Interest expenses
-€1.01M - EBT
-€32.04M - Tax expenses
€1.79M - Net income
-€33.83M
Cash flow statement
- Net deferred tax
-€10.79M - Non-cash items
-€5.42M - Changes in working capital
€1.97M - Operating cash flow
-€41.51M - Capex
€2.71M - Other investing cash flow
€31.88K - Net investing cash flow
-€2.67M - Total cash dividends paid
€0.00 - Issuance of common stock
€6.68M - Debt repayment
€0.00 - Other financing cash flow
€4.64M - Net financing cash flow
€4.64M - Foreign exchange effects
€0.00 - Net change in cash
-€29.41M - Cash at end of period
€17.89M - Free cash flow
-€38.81M
Balance sheet
- Cash and cash equivalents
€17.35M - Cash and short-term investments
€17.35M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€3.68M - Total current assets
€21.03M - Property, plant & equipment
€11.63M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€761.61K - Total non-current assets
€12.39M - Total assets
€33.42M - Accounts payable
€511.76K - Short-term debt
€6.13M - Other current liabilities
€7.55M - Total current liabilities
€15.53M - Long-term debt
€7.21M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€7.21M - Total liabilities
€22.75M - Common stock
€50.83K - Retained earnings
-€365.16M - Other equity
€0.00 - Total equity
€10.67M - Total liabilities and shareholders' equity
€33.42M
Company information
- Market capitalization
€0.00 - Employees
74 - Enterprise Value
-€26.02M
Company ratios
- Gross margin
-
100.0% Much better than peer group: -436.3% - EBITDA margin
-
-13,774.8% Much worse than peer group: -4,004.4% - EBIT margin
-
-20,525.2% Much worse than peer group: -4,500.8% - EBT margin
-
-13,774.4% Much worse than peer group: -5,271.0% - Net margin
-
-14,542.6% Much worse than peer group: -4,624.3% - ROE
-
-317.0% Much worse than peer group: -96.6% - ROA
-
-101.2% Much better than peer group: -1,444.1% - Asset turnover
-
0.7% Much worse than peer group: 767.6% - FCF margin
-
-19,009.6% Much worse than peer group: -4,039.1% - FCF yield
0.0% - Efficiency ratio
13,874.8% - Net sales per employee
-
€3.14K - Net income per employee
-
-€457.14K